期刊
NUCLEAR MEDICINE AND BIOLOGY
卷 37, 期 1, 页码 3-8出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.nucmedbio.2009.08.013
关键词
Tetrabenazine; Dopamine; Tomography, emission computed; Vesicular monoamine transporter; alpha-Methyl-p-tyrosine
资金
- Office of Science (BER), US Department of Energy [DE-FG02-87ER60561]
- National Institutes of Health [NS15655]
- NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK077493, R01DK063567] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS015655, P01NS015655] Funding Source: NIH RePORTER
Introduction: The sensitivity of the in vivo binding of [C-11]dihydrotetrabenazine ([C-11]DTBZ) and [C-11]methylphenidate ([C-11]MPH) to their respective targets - vesicular monoamine transporter type 2 (VMAT2) and neuronal membrane dopamine transporter after alterations in endogenous levels of dopamine was examined in the rat brain. Methods: In vivo binding of [C-11]DTBZ and [C-11]MPH was determined using a bolus+infusion protocol. The in vitro number of VMAT2 binding sites was determined by autoradiography. Results: Repeated dosing with alpha-methyl-p-tyrosine (AMPT) at doses that significantly (-75%) depleted brain tissue dopamine levels resulted in increased (+36%) in vivo [C-11]DTBZ binding to VMAT2 in the striatum. The increase in binding could be completely reversed via treatment with L-DOPA/benserazide to restore dopamine levels. There were no changes in the total number of VMAT2 binding sites, as measured using in vitro autoradiography. No changes were observed for in vivo [C-11]MPH binding to the dopamine transporter in the striatum following AMPT pretreatment. Conclusion: These results indicate that large reductions in dopamine concentrations in the rat brain can produce modest but significant changes in the binding of radioligands to VMAT2, which can be reversed by replenishment of dopamine using exogenous L-DOPA. (C) 2010 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据